Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoxetine in Pediatric Body Dysmorphic Disorder
NCT00245635Phase 4Completed
- Sponsor
- Montefiore Medical Center
- Start
- Nov 2004
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in body dysmorphic disorder (BDD) comparing Fluoxetine with Placebo (2 arms). Primary endpoint: Yale-Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder at 12 weeks. Started Nov 2004; status: completed.
02
Drugs
fluoxetine
03
Conditions
body dysmorphic disorder (BDD)
Beyond the preview
Go deeper on NCT00245635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00245635.